Antibody-Based CAR-T Cells Targeting BAFF-R therapy (Iaso Biotherapeutics)

N/A

Report date: 2024/12/20 15:49:49

Base Information

Drug NameAntibody-Based CAR-T Cells Targeting BAFF-R therapy (Iaso Biotherapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell activating factor receptor modulatorsT lymphocyte replacements
TargetsB-cell activating factor receptor
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesIaso Biotherapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical SchoolIaso Biotherapeutics Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A